A number of other brokerages have also recently commented on ZTS. BMO Capital Markets reaffirmed a hold rating and set a $65.00 price target on shares of Zoetis in a research report on Thursday, November 2nd. Morgan Stanley raised Zoetis from an equal weight rating to an overweight rating and set a $80.00 price target for the company in a research report on Wednesday, November 29th. UBS Group reaffirmed a neutral rating on shares of Zoetis in a research report on Friday, November 24th. Citigroup raised Zoetis from a neutral rating to a buy rating and set a $85.00 price target for the company in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald set a $85.00 price objective on Zoetis and gave the company a buy rating in a report on Thursday, January 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $79.83.
Shares of Zoetis (ZTS) opened at $79.73 on Thursday. Zoetis has a 52-week low of $52.25 and a 52-week high of $81.40. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The company has a market capitalization of $38,850.00, a PE ratio of 36.57, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.83% and a net margin of 16.28%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the previous year, the firm posted $0.47 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. equities analysts forecast that Zoetis will post 3.02 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be issued a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.63%. Zoetis’s dividend payout ratio (DPR) is presently 22.94%.
Several hedge funds have recently modified their holdings of ZTS. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Zoetis in the 4th quarter valued at about $108,000. Steward Partners Investment Advisory LLC purchased a new position in shares of Zoetis in the 3rd quarter valued at about $114,000. We Are One Seven LLC purchased a new position in shares of Zoetis in the 4th quarter valued at about $120,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares in the last quarter. Finally, Premia Global Advisors LLC purchased a new position in shares of Zoetis in the 4th quarter valued at about $122,000. 93.72% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2018/02/19/cowen-analysts-give-zoetis-zts-a-85-00-price-target.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.